We Believe XOMA Royalty's (NASDAQ:XOMA) Earnings Are A Poor Guide For Its Profitability

XOMA Royalty Announces Closing of Its Acquisition by Ligand

Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets

Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator

Royalty Powerhouse: Ligand And Xoma Unite In $739 Million Deal

CG Oncology, Inc. (CGON) Reports Q1 Loss, Tops Revenue Estimates

Oncobiologics, Inc. (OTLK) Reports Q2 Loss, Lags Revenue Estimates

XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date

Ligand Pharmaceuticals (LGND) Stock Looks Undervalued On Cash Flow Yet Overvalued On Earnings

XOMA Royalty (XOMA) Stock Fair Value Falls After Ligand Agrees Cash Acquisition